MARKET

SNGX

SNGX

Soligenix Inc
NASDAQ
1.180
+0.070
+6.31%
After Hours: 1.160 -0.02 -1.71% 18:15 03/31 EDT
OPEN
1.100
PREV CLOSE
1.110
HIGH
1.200
LOW
1.080
VOLUME
202.06K
TURNOVER
--
52 WEEK HIGH
6.23
52 WEEK LOW
1.000
MARKET CAP
11.90M
P/E (TTM)
-0.3225
1D
5D
1M
3M
1Y
5Y
1D
Soligenix GAAP EPS of -$2.14 beats by $0.01
Seeking Alpha · 13h ago
SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND YEAR END 2025 FINANCIAL RESULTS
Reuters · 13h ago
Weekly Report: what happened at SNGX last week (0323-0327)?
Weekly Report · 1d ago
Soligenix publishes corporate presentation; pipeline targets rare diseases with ~$2 billion in potential global annual sales
Reuters · 5d ago
Soligenix (NASDAQ: SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behçet Disease
TipRanks · 5d ago
Soligenix Secures EU Orphan Drug Status For Rare Disease Treatment, Designation Provides 10-Year Market Exclusivity And Development Support
Benzinga · 5d ago
Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease
TipRanks · 5d ago
Soligenix shares rise; European Commission grants orphan drug designation for SGX945 in Behçet's disease
Reuters · 5d ago
More
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

Webull offers Soligenix Inc stock information, including NASDAQ: SNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNGX stock methods without spending real money on the virtual paper trading platform.